Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies …

EA Stein, RP Giugliano, MJ Koren, FJ Raal… - European heart …, 2014 - academic.oup.com
Aims Prior trials with monoclonal antibodies to proprotein convertase subtilizin/kexin type 9
(PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However …
被引用次数：148 相关文章
[PDF] academia.edu

[PDF][PDF] Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies …

EA Stein, RP Giugliano, MJ Koren, FJ Raal… - European Heart …, 2014 - academia.edu
Aims Prior trials with monoclonal antibodies to proprotein convertase subtilizin/kexin type 9
(PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However …

[引用][C] Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies …

EA Stein, RP Giugliano, MJ Koren, FJ Raal… - European Heart …, 2014 - cir.nii.ac.jp
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in
hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 …
[PDF] archive.org

[PDF][PDF] Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies …

EA Stein, RP Giugliano, MJ Koren, FJ Raal… - European Heart …, 2014 - scholar.archive.org
Aims Prior trials with monoclonal antibodies to proprotein convertase subtilizin/kexin type 9
(PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However …
[PDF] researchgate.net

[PDF][PDF] Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies …

EA Stein, RP Giugliano, MJ Koren, FJ Raal… - European Heart …, 2014 - researchgate.net
Aims Prior trials with monoclonal antibodies to proprotein convertase subtilizin/kexin type 9
(PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However …

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies …

EA Stein, RP Giugliano, MJ Koren… - European heart …, 2014 - pubmed.ncbi.nlm.nih.gov
Aims Prior trials with monoclonal antibodies to proprotein convertase subtilizin/kexin type 9
(PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However …

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies …

EA Stein, RP Giugliano, MJ Koren, FJ Raal… - European Heart …, 2014 - europepmc.org
Aims Prior trials with monoclonal antibodies to proprotein convertase subtilizin/kexin type 9
(PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However …

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies …

EA Stein, RP Giugliano, MJ Koren, FJ Raal… - European Heart …, 2014 - hero.epa.gov
AIMS: Prior trials with monoclonal antibodies to proprotein convertase subtilizin/kexin type 9
(PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However …

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies …

EA Stein, RP Giugliano, MJ Koren… - European Heart …, 2014 - search.ebscohost.com
Aims Prior trials with monoclonal antibodies to proprotein convertase subtilizin/kexin type 9
(PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However …
[PDF] academia.edu

[PDF][PDF] Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies …

EA Stein, RP Giugliano, MJ Koren, FJ Raal… - European Heart …, 2014 - academia.edu
Aims Prior trials with monoclonal antibodies to proprotein convertase subtilizin/kexin type 9
(PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However …